Beijing Memorial Pharmaceutical Research and Development Co.,Ltd.
+86 15810509002
Lang. :
English
中 文
☰
Home
Semaglutide
Main Business
International Purchasement of Comparator
Exportation of R&D Drugs
Comparator Import & Export
Storage and Logistics of Investigational Product
Repackage of The Investigational Product
Clinical Trial Subjects Recruitment
R&D Products
News
Latest News
NDA News
Clinical News
Industrial News
Company Update
About Us
About CliniExpert
R&D center
Production base
Big Events
Photo Wall
Clinical Viewpoint
Talent Recruitment
Home
News
· R&D Products
Vortioxetine Hydrobromide Tablets
CliniExpert
•
2019/11/04
360
•
0
氢溴酸沃替西汀片
Return
Hot Info
FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
FDA Approves Penpulimab-kcqx for the Treatment of Advanced Nasopharyngeal Carcinoma
FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin
FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
15810509002
